GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » RemeGen Co Ltd (HKSE:09995) » Definitions » Current Accrued Expense

RemeGen Co (HKSE:09995) Current Accrued Expense : HK$0.0 Mil (As of Dec. 2023)


View and export this data going back to 2020. Start your Free Trial

What is RemeGen Co Current Accrued Expense?

RemeGen Co's Current Accrued Expense for the quarter that ended in Dec. 2023 was HK$0.0 Mil.


RemeGen Co Current Accrued Expense Historical Data

The historical data trend for RemeGen Co's Current Accrued Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

RemeGen Co Current Accrued Expense Chart

RemeGen Co Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Current Accrued Expense
Get a 7-Day Free Trial - - - - -

RemeGen Co Quarterly Data
Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Sep22 Dec22 Jun23 Sep23 Dec23 Mar24
Current Accrued Expense Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

RemeGen Co Current Accrued Expense Calculation

Current Accrued Expense is the expense incurred during the accounting period, but not required to be paid until a later date. It includes compensation, interest, pensions and all other miscellaneous accruals reported by the company.


RemeGen Co Current Accrued Expense Related Terms

Thank you for viewing the detailed overview of RemeGen Co's Current Accrued Expense provided by GuruFocus.com. Please click on the following links to see related term pages.


RemeGen Co (HKSE:09995) Business Description

Traded in Other Exchanges
Address
58 Middle Beijing Road, Yantai Area of Shandong Pilot Free Trade Zone, Yantai Development Zone, Yantai, CHN
RemeGen was established in 2008 and listed on the Hong Kong Stock Exchange in 2020. It is a commercial stage biotech company focused on developing drugs to treat autoimmune disease, cancer, and ophthalmic disease for the China market and potentially the global market, as well. Its core assets are disitamab vedotin (RC48), a HER2-targeting antibody-drug conjugate (ADC) for treating HER2-expressing cancers, and telitacicept (RC18), a BLyS and APRIL targeting bispecific fusion protein for treating various B-cell mediated autoimmune diseases. These drugs received their first approvals in China in 2021 and are both covered on the National Reimbursement Drug List (NRDL).

RemeGen Co (HKSE:09995) Headlines

No Headlines